Table of Contents
Hepatitis Research and Treatment
Volume 2014, Article ID 860562, 11 pages
http://dx.doi.org/10.1155/2014/860562
Research Article

MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection

1Immunotope, Inc., Doylestown, PA 18902, USA
2Baylor College of Medicine, Houston, TX 77030, USA
3Celldex Therapeutics, Hampton, NJ 08827, USA

Received 6 March 2014; Revised 9 April 2014; Accepted 18 April 2014; Published 26 May 2014

Academic Editor: Piero Luigi Almasio

Copyright © 2014 Joseph D. Comber et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B,” Hepatology, vol. 34, no. 6, pp. 1225–1241, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Rehermann and M. Nascimbeni, “Immunology of hepatitis B virus and hepatitis C virus infection,” Nature Reviews Immunology, vol. 5, no. 3, pp. 215–229, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Bertoletti and A. J. Gehring, “The immune response during hepatitis B virus infection,” Journal of General Virology, vol. 87, part 6, pp. 1439–1449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. C. W. Shepard, E. P. Simard, L. Finelli, A. E. Fiore, and B. P. Bell, “Hepatitis B virus infection: epidemiology and vaccination,” Epidemiologic Reviews, vol. 28, no. 1, pp. 112–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Lavanchy, “Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 97–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. L. G. Guidotti, T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari, “Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes,” Immunity, vol. 4, no. 1, pp. 25–36, 1996. View at Google Scholar
  7. L. G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari, “Viral clearance without destruction of infected cells during acute HBV infection,” Science, vol. 284, no. 5415, pp. 825–829, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Thimme, S. Wieland, C. Steiger et al., “CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection,” Journal of Virology, vol. 77, no. 1, pp. 68–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. J. Chang and S. R. Lewin, “Immunopathogenesis of hepatitis B virus infection,” Immunology and Cell Biology, vol. 85, no. 1, pp. 16–23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. J. M. Webster, S. Reignat, M. K. Maini et al., “Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms,” Hepatology, vol. 32, no. 5, pp. 1117–1124, 2000. View at Google Scholar · View at Scopus
  11. C. Ferrari, A. Penna, A. Bertoletti et al., “Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection,” Journal of Immunology, vol. 145, no. 10, pp. 3442–3449, 1990. View at Google Scholar · View at Scopus
  12. B. Rehermann, P. Fowler, J. Sidney et al., “The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis,” Journal of Experimental Medicine, vol. 181, no. 3, pp. 1047–1058, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. C. P. Desmond, A. Bartholomeusz, S. Gaudieri, P. A. Revill, and S. R. Lewin, “A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics,” Antiviral Therapy, vol. 13, no. 2, pp. 161–175, 2008. View at Google Scholar · View at Scopus
  14. B. Rehermann, D. Lau, J. H. Hoofnagle, and F. V. Chisari, “Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection,” The Journal of Clinical Investigation, vol. 97, no. 7, pp. 1655–1665, 1996. View at Google Scholar
  15. D.-Z. Xu, K. Zhao, L.-M. Guo et al., “A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients,” PLoS ONE, vol. 3, no. 7, Article ID e2565, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. D. Livingston, C. Crimi, H. Grey et al., “The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection,” Journal of Immunology, vol. 159, no. 3, pp. 1383–1392, 1997. View at Google Scholar
  17. M. Mancini-Bourgine, H. Fontaine, D. Scott-Algara, S. Pol, C. Bréchot, and M.-L. Michel, “Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers,” Hepatology, vol. 40, no. 4, pp. 874–882, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Pancholi, D.-H. Lee, Q. Liu et al., “DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee,” Hepatology, vol. 33, no. 2, pp. 448–454, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Sette, A. Vitiello, B. Reherman et al., “The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes,” Journal of Immunology, vol. 153, no. 12, pp. 5586–5592, 1994. View at Google Scholar · View at Scopus
  20. J. S. Testa, V. Shetty, J. Hafner et al., “MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response,” PLoS ONE, vol. 7, no. 11, Article ID e48484, 2012. View at Publisher · View at Google Scholar
  21. J. S. Testa, V. Shetty, G. Sinnathamby et al., “Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response,” The Journal of Infectious Diseases, vol. 205, no. 4, pp. 647–655, 2012. View at Publisher · View at Google Scholar
  22. V. Shetty, Z. Nickens, J. Testa, J. Hafner, G. Sinnathamby, and R. Philip, “Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells,” Journal of Proteomics, vol. 75, no. 11, pp. 3270–3290, 2012. View at Publisher · View at Google Scholar
  23. V. Shetty, G. Sinnathamby, Z. Nickens et al., “MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response,” Journal of Proteomics, vol. 74, no. 5, pp. 728–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. K. T. Hogan, M. A. Coppola, C. L. Gatlin et al., “Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes,” Immunology Letters, vol. 90, no. 2-3, pp. 131–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Feyerabend, S. Stevanovic, C. Gouttefangeas et al., “Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer,” Prostate, vol. 69, no. 9, pp. 917–927, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. O. E. Hawkins, R. S. Vangundy, A. M. Eckerd et al., “Identification of breast cancer peptide epitopes presented by HLA-A*0201,” Journal of Proteome Research, vol. 7, no. 4, pp. 1445–1457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. K. T. Hogan, M. A. Coppola, C. L. Gatlin et al., “Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma,” Cancer Research, vol. 64, no. 3, pp. 1157–1163, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. H.-G. Rammensee, J. Bachmann, N. P. N. Emmerich, O. A. Bachor, and S. Stevanović, “SYFPEITHI: database for MHC ligands and peptide motifs,” Immunogenetics, vol. 50, no. 3-4, pp. 213–219, 1999. View at Google Scholar · View at Scopus
  29. M. R. Betts, J. M. Brenchley, D. A. Price et al., “Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation,” Journal of Immunological Methods, vol. 281, no. 1-2, pp. 65–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. E. A. Mittendorf, C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples, “Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides,” Breast Cancer Research and Treatment, vol. 92, no. 1, pp. 85–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Parmigiani, M. L. Alcaide, R. Freguja et al., “Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation,” PLoS ONE, vol. 8, no. 11, Article ID e79816, 2013. View at Publisher · View at Google Scholar
  32. J. K. Nieminen, M. Niemi, T. Sipponen et al., “Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling,” PLoS ONE, vol. 8, no. 8, Article ID e70738, 2013. View at Publisher · View at Google Scholar
  33. S. Malmassari, Y. C. Lone, M. Zhang, C. Transy, and M.-L. Michel, “In vivo hierarchy of immunodominant and subdominant HLA-A*0201- restricted T-cell epitopes of HBx antigen of hepatitis B virus,” Microbes and Infection, vol. 7, no. 4, pp. 626–634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. E. J. Wherry, J. N. Blattman, K. Murali-Krishna, R. Van Der Most, and R. Ahmed, “Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment,” Journal of Virology, vol. 77, no. 8, pp. 4911–4927, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. R. G. van der Most, K. Murali-Krishna, J. G. Lanier et al., “Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation,” Virology, vol. 315, no. 1, pp. 93–102, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. P. J. R. Goulder, M. A. Altfeld, E. S. Rosenberg et al., “Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection,” Journal of Experimental Medicine, vol. 193, no. 2, pp. 181–193, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. E. R. Jellison, M. J. Turner, D. A. Blair et al., “Distinct mechanisms mediate naive and memory CD8 T-cell tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 52, pp. 21438–21443, 2012. View at Publisher · View at Google Scholar
  38. M. D. Martin, S. A. Condotta, J. T. Harty, and V. P. Badovinac, “Population dynamics of naive and memory CD8 T cell responses after antigen stimulations in vivo,” Journal of Immunology, vol. 188, no. 3, pp. 1255–1265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. E. R. Mehlhop-Williams and M. J. Bevan, “Memory CD8+ T cells exhibit increased antigen threshold requirements for recall proliferation,” The Journal of Experimental Medicine, vol. 211, no. 2, pp. 345–356, 2014. View at Publisher · View at Google Scholar
  40. A. J. Gehring, D. Sun, P. T. F. Kennedy et al., “The level of viral antigen presented by hepatocytes influences CD8 T-cell function,” Journal of Virology, vol. 81, no. 6, pp. 2940–2949, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Lechner, D. K. Wong, P. R. Dunbar et al., “Analysis of successful immune responses in persons infected with hepatitis C virus,” The Journal of Experimental Medicine, vol. 191, no. 9, pp. 1499–1512, 2000. View at Google Scholar
  42. N. H. Shoukry, A. G. Cawthon, and C. M. Walker, “Cell-mediated immunity and the outcome of hepatitis C virus infection,” Annual Review of Microbiology, vol. 58, pp. 391–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Vitiello, G. Ishioka, H. M. Grey et al., “Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans,” The Journal of Clinical Investigation, vol. 95, no. 1, pp. 341–349, 1995. View at Google Scholar · View at Scopus
  44. R. Schirmbeck, P. Riedl, N. Fissolo, F. A. Lemonnier, A. Bertoletti, and J. Reimann, “Translation from cryptic reading frames of DNA vaccines generates an extended repertoire of immunogenic, MHC class I-restricted epitopes,” Journal of Immunology, vol. 174, no. 8, pp. 4647–4656, 2005. View at Google Scholar · View at Scopus
  45. P. Buchmann, C. Dembek, L. Kuklick et al., “A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice,” Vaccine, vol. 31, no. 8, pp. 1197–1203, 2013. View at Publisher · View at Google Scholar
  46. S. Pol, B. Nalpas, F. Driss et al., “Efficacy and limitations of a specific immunotherapy in chronic hepatitis B,” Journal of Hepatology, vol. 34, no. 6, pp. 917–921, 2001. View at Publisher · View at Google Scholar · View at Scopus